Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Conditions:
Metastatic Breast Cancer
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Who can participate
Inclusion Criteria:
* Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.
Locations
14
Australia (1)
Liverpool Hospital
Liverpool , New South Wales
Canada (1)
Tom Baker Cancer Center
Calgary , Alberta
Egypt (1)
Cairo Oncology Center (Cairo Cure)
Mohandeseen , Cairo Governorate
India (1)
Apollo Cancer Institute, Apollo Speciality Hospital
Teynampet , Chennai
Italy (1)
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
БГ